AZD 4954
Alternative Names: AZD-4954Latest Information Update: 30 May 2025
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 26 May 2025 AstraZeneca plans a phase I trial (In volunteers) in USA (PO) in May 2025 (NCT06980428)
- 20 May 2025 Preclinical trials in Unspecified in United Kingdom (PO) before May 2025